PSI Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-568
Closed -$63.6K 313
2025
Q1
$63.6K Hold
568
0.02% 212
2024
Q4
$52.5K Hold
568
0.02% 264
2024
Q3
$47.6K Sell
568
-400
-41% -$30.5K 0.01% 280
2024
Q2
$66.4K Buy
968
+185
+24% +$12.3K 0.02% 221
2024
Q1
$57.4K Sell
783
-80
-9% -$6.15K 0.02% 236
2023
Q4
$69.9K Hold
863
0.03% 222
2023
Q3
$64.7K Hold
863
0.03% 225
2023
Q2
$66.5K Sell
863
-4
-0.5% -$319 0.03% 212
2023
Q1
$71.9K Sell
867
-650
-43% -$53.8K 0.03% 187
2022
Q4
$130K Sell
1,517
-8,270
-84% -$655K 0.07% 134
2022
Q3
$603K Sell
9,787
-1,125
-10% -$70.9K 0.32% 61
2022
Q2
$674K Buy
10,912
+465
+4% +$28.8K 0.33% 65
2022
Q1
$621K Sell
10,447
-268
-3% -$17.1K 0.26% 76
2021
Q4
$778K Buy
10,715
+223
+2% +$15.4K 0.32% 67
2021
Q3
$733K Buy
10,492
+247
+2% +$17.4K 0.34% 62
2021
Q2
$705K Buy
10,245
+180
+2% +$12K 0.37% 59
2021
Q1
$650K Buy
10,065
+750
+8% +$48.4K 0.38% 59
2020
Q4
$542K Sell
9,315
-832
-8% -$50.2K 0.37% 63
2020
Q3
$641K Buy
10,147
+3,870
+62% +$268K 0.49% 45
2020
Q2
$482K Sell
6,277
-3,408
-35% -$261K 0.39% 58
2020
Q1
$724K Buy
9,685
+2,575
+36% +$178K 0.67% 32
2019
Q4
$462K Buy
+7,110
New +$463K 0.3% 70

Other funds holding GILD

PSI Advisors's GILD Position: Q2 2025 in Review

PSI Advisors sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 568 shares — an estimated $63.6K sold.

PSI Advisors first reported a position in GILD in Q4 2019 and held it in 22 quarters. The position peaked at $778K in Q4 2021. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • PSI Advisors reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • PSI Advisors sold 568 Gilead Sciences shares in Q2 2025, an estimated $63.6K.
  • PSI Advisors first reported a position in Gilead Sciences in Q4 2019 and held it in 22 quarters.
  • PSI Advisors's Gilead Sciences position peaked at $778K in Q4 2021.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.